PSGL-1 Immune Checkpoint Inhibition for CD4(+) T Cell Cancer Immunotherapy

Immune checkpoint inhibition targeting T cells has shown tremendous promise in the treatment of many cancer types and are now standard therapies for patients. While standard therapies have focused on PD-1 and CTLA-4 blockade, additional immune checkpoints have shown promise in promoting anti-tumor i...

Descripción completa

Detalles Bibliográficos
Autores principales: DeRogatis, Julia M., Viramontes, Karla M., Neubert, Emily N., Tinoco, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940186/
https://www.ncbi.nlm.nih.gov/pubmed/33708224
http://dx.doi.org/10.3389/fimmu.2021.636238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940186/
https://www.ncbi.nlm.nih.gov/pubmed/33708224
http://dx.doi.org/10.3389/fimmu.2021.636238

Ejemplares similares